2024
CRISPR-based dissection of microRNA-23a ~ 27a ~ 24-2 cluster functionality in hepatocellular carcinoma
Cui M, Liu Z, Wang S, Bae S, Guo H, Zhou J, Liu R, Wang L. CRISPR-based dissection of microRNA-23a ~ 27a ~ 24-2 cluster functionality in hepatocellular carcinoma. Oncogene 2024, 43: 2708-2721. PMID: 39112518, PMCID: PMC11364504, DOI: 10.1038/s41388-024-03115-z.Peer-Reviewed Original ResearchConceptsMiR-23aMiR-27aCRISPR interferenceCRISPR activationHigh-throughput RNA-seqCell migrationCDK1/cyclin B activityReduced cell growth in vitroMiRNA target predictionCell cycle arrestMiRNA clusterHepatocellular carcinoma cellsCell growth in vitroRNA-seqGene networksTarget predictionCRISPR knockoutOncogenic roleGrowth in vitroCycle arrestMature miRNAsMiRNAsG2/M phaseSignaling pathwayOncogenic function
2019
Enhancement of sorafenib-mediated death of Hepatocellular carcinoma cells by Carnosic acid and Vitamin D2 analog combination
Wu Q, Wang X, Pham K, Luna A, Studzinski GP, Liu C. Enhancement of sorafenib-mediated death of Hepatocellular carcinoma cells by Carnosic acid and Vitamin D2 analog combination. The Journal Of Steroid Biochemistry And Molecular Biology 2019, 197: 105524. PMID: 31704246, PMCID: PMC7015782, DOI: 10.1016/j.jsbmb.2019.105524.Peer-Reviewed Original ResearchConceptsHepatocellular carcinomaVitamin DOral multi-kinase inhibitorTreatment of HCCAutophagy markers Beclin1Vitamin D insufficiencyCarnosic acidAdvanced hepatocellular carcinomaPromising therapeutic optionVitamin D analogsMulti-kinase inhibitorCell linesElevated protein levelsAnti-oxidant propertiesHCC cell linesHuman neoplastic cellsD insufficiencyGlobal cancer mortalityHepatocellular carcinoma cellsSystemic treatmentTherapeutic optionsCancer mortalityHCC cell deathPreclinical studiesLiver cancer
2017
Augmentation of Anticancer Drug Efficacy in Murine Hepatocellular Carcinoma Cells by a Peripherally Acting Competitive N‑Methyl‑d‑aspartate (NMDA) Receptor Antagonist
Gynther M, Silvestri I, Hansen J, Hansen K, Malm T, Ishchenko Y, Larsen Y, Han L, Kayser S, Auriola S, Petsalo A, Nielsen B, Pickering D, Bunch L. Augmentation of Anticancer Drug Efficacy in Murine Hepatocellular Carcinoma Cells by a Peripherally Acting Competitive N‑Methyl‑d‑aspartate (NMDA) Receptor Antagonist. Journal Of Medicinal Chemistry 2017, 60: 9885-9904. PMID: 29205034, PMCID: PMC5788303, DOI: 10.1021/acs.jmedchem.7b01624.Peer-Reviewed Original ResearchConceptsMurine hepatocellular carcinoma cellsHepatocellular carcinoma cellsN-methyl-D-aspartate receptor antagonistCompetitive N-methyl-D-aspartate (NMDA) receptor antagonistMultidrug resistanceCarcinoma cellsCancer cellsCommon solid tumorsNMDA receptor inhibitionIntrinsic multidrug resistanceReceptor antagonistReceptor inhibitionAnticancer drug efficacyUnderlying biological mechanismsSolid tumorsDrug efficacyReduced expressionCytotoxic actionSorafenibStructure-activity studiesMDR transportersAnticancer drugsBiological mechanismsCellsPromising strategyReticulocalbin-2 enhances hepatocellular carcinoma proliferation via modulating the EGFR-ERK pathway
Ding D, Huang H, Jiang W, Yu W, Zhu H, Liu J, Saiyin H, Wu J, Huang H, Jiang S, Yu L. Reticulocalbin-2 enhances hepatocellular carcinoma proliferation via modulating the EGFR-ERK pathway. Oncogene 2017, 36: 6691-6700. PMID: 28745317, DOI: 10.1038/onc.2017.230.Peer-Reviewed Original ResearchMeSH KeywordsAnimalsAntineoplastic AgentsCalcium-Binding ProteinsCarcinoma, HepatocellularCell Line, TumorCell ProliferationCell SurvivalErbB ReceptorsFemaleHumansLiver NeoplasmsMaleMAP Kinase Signaling SystemMice, NudeMiddle AgedNeoplasm TransplantationProtein Kinase InhibitorsProtein MultimerizationTumor BurdenConceptsEpidermal growth factor receptorEGFR-ERK pathwayHepatocellular carcinomaEGFR-ERKReticulocalbin-2Tumor growthCell proliferationDownregulated cyclin D1 expressionEpidermal growth factor receptor phosphorylationTherapeutic target of hepatocellular carcinomaKi-67 expressionTyrosine kinase inhibitorsG1/S transition arrestHepatocellular carcinoma patientsTargeting of hepatocellular carcinomaGrowth factor receptorExposure to EGFCyclin D1 expressionDisease recurrenceTumor sizeNon-tumor tissuesHepatocellular carcinoma cellsKi-67RCN2 expressionHCC cell proliferationScience to Practice: Killing Dormant Cells—Is Targeting Autophagy the Key to Complete Tumor Response in Transarterial Chemoembolization?
Savic LJ, Chapiro J, Geschwind JF. Science to Practice: Killing Dormant Cells—Is Targeting Autophagy the Key to Complete Tumor Response in Transarterial Chemoembolization? Radiology 2017, 283: 621-623. PMID: 28514219, DOI: 10.1148/radiol.2017170358.Peer-Reviewed Original Research
2016
A novel KLF6-Rho GTPase axis regulates hepatocellular carcinoma cell migration and dissemination
Ahronian L, Zhu L, Chen Y, Chu H, Klimstra D, Lewis B. A novel KLF6-Rho GTPase axis regulates hepatocellular carcinoma cell migration and dissemination. Oncogene 2016, 35: 4653-4662. PMID: 26876204, PMCID: PMC4985511, DOI: 10.1038/onc.2016.2.Peer-Reviewed Original ResearchMeSH KeywordsAnimalsCarcinoma, HepatocellularCell Line, TumorCell MovementDisease Models, AnimalGene Expression Regulation, NeoplasticGene Knockdown TechniquesHumansKruppel-Like Factor 6Kruppel-Like Transcription FactorsLiver NeoplasmsMiceNeuropeptidesProto-Oncogene ProteinsProto-Oncogene Proteins c-vavrac1 GTP-Binding ProteinSignal TransductionConceptsHepatocellular carcinoma cell migrationGene expression profilesCell migrationHepatocellular carcinomaRac1 small GTPaseSingle-copy deletionCarcinoma cell migrationSmall GTPasesMurine HCC cell linesDevelopment of distant metastasesPresence of vascular invasionHCC cell migrationChromatin immunoprecipitationRac1 activationHepatocellular carcinoma mouse modelDeep sequencingHCC cell linesPotential curative optionHepatocellular carcinoma cellsTranscriptional targetsHuman hepatocellular carcinomaIncreased tumor formationPresence of invasionRac1Hepatocellular carcinoma development
2014
Epigenetic regulation of OPA1 sensitizes hepatocellular carcinoma to sorafenib‐induced apoptosis (59.1)
Puszyk W, Dong H, Zhao F, Shisgal P, Cabrera R, Neslon D, Liu C. Epigenetic regulation of OPA1 sensitizes hepatocellular carcinoma to sorafenib‐induced apoptosis (59.1). The FASEB Journal 2014, 28 DOI: 10.1096/fasebj.28.1_supplement.59.1.Peer-Reviewed Original ResearchDNA methylationHepatocellular carcinomaEpigenetic regulationProtein OPA1HCC cellsMitochondrial fragmentationGene promoterC releaseEpigenetic analysisXenograft tumor growthEpigenetic markersSorafenib-induced apoptosisAkt pathwayOPA1HCC xenograft tumor growthHepatocellular carcinoma cellsNovel therapeutic targetExpression levelsTumorigenesis of HCCIdentification of patientsPathogenesis of HCCOPA1 knockdownApoptosisPrimary hepatocytesSensitivity of HCC
2011
Survivin Inhibition Is Critical for Bcl-2 Inhibitor-Induced Apoptosis in Hepatocellular Carcinoma Cells
Zhao X, Ogunwobi O, Liu C. Survivin Inhibition Is Critical for Bcl-2 Inhibitor-Induced Apoptosis in Hepatocellular Carcinoma Cells. PLOS ONE 2011, 6: e21980. PMID: 21829603, PMCID: PMC3148218, DOI: 10.1371/journal.pone.0021980.Peer-Reviewed Original ResearchConceptsBcl-2 inhibitorsCombination treatmentHCC cellsABT-263Survivin inhibitionHepatocellular carcinomaHuman liver cancer tissuesSingle treatmentFuture clinical trialsApoptotic effectsLiver cancer tissuesLiver cancer therapyERK activationHCC cell linesHepatocellular carcinoma cellsPreclinical dataClinical trialsTherapeutic effectLow doseNormal human hepatocytesCancer tissuesYM-155High dosesNovel Bcl-2 inhibitorABT-263-induced apoptosisDNA Methylation Suppresses Expression of the Urea Cycle Enzyme Carbamoyl Phosphate Synthetase 1 (CPS1) in Human Hepatocellular Carcinoma
Liu H, Dong H, Robertson K, Liu C. DNA Methylation Suppresses Expression of the Urea Cycle Enzyme Carbamoyl Phosphate Synthetase 1 (CPS1) in Human Hepatocellular Carcinoma. American Journal Of Pathology 2011, 178: 652-661. PMID: 21281797, PMCID: PMC3069978, DOI: 10.1016/j.ajpath.2010.10.023.Peer-Reviewed Original ResearchMeSH KeywordsCarbamoyl-Phosphate Synthase (Ammonia)Carcinoma, HepatocellularCell Line, TumorCpG IslandsDNA MethylationGene Expression Regulation, EnzymologicGene Expression Regulation, NeoplasticHepatocyte Nuclear Factor 3-betaHepatocytesHumansLiver NeoplasmsPromoter Regions, GeneticQuaternary Ammonium CompoundsRNA, MessengerUreaConceptsHCC cellsNoncancerous tissuesTumor tissueHepatocyte paraffin 1 antibodySurgical pathology practiceLiver cancer tissuesHuman HCC cellsCPS1 expressionHCC tumor tissuesLiver tumor tissuesHuman hepatocellular carcinomaHuman hepatocellular carcinoma cellsCultured human primary hepatocytesHuman primary hepatocytesHepatocellular carcinoma cellsHepatocellular carcinomaCPS1 geneRate-limiting enzymeLiver carcinogenesisCancer tissuesSynthetase 1Potential biomarkersCarbamoyl phosphate synthetase 1Pathology practiceCarcinoma cells
2007
Loss of p53 and Ink4a/Arf Cooperate in a Cell Autonomous Fashion to Induce Metastasis of Hepatocellular Carcinoma Cells
Chen Y, Klimstra D, Mongeau M, Tatem J, Boyartchuk V, Lewis B. Loss of p53 and Ink4a/Arf Cooperate in a Cell Autonomous Fashion to Induce Metastasis of Hepatocellular Carcinoma Cells. Cancer Research 2007, 67: 7589-7596. PMID: 17699762, PMCID: PMC2396788, DOI: 10.1158/0008-5472.can-07-0381.Peer-Reviewed Original ResearchConceptsTumor suppressor locusHepatocellular carcinomaSuppressor locusInvasive activity in vitroINK4a/ARF tumor suppressor locusMetastatic HCC modelP53 loss of functionLoss of p53Cell-autonomous fashionHepatocellular carcinoma patientsCancer-related deathsMetastasis of hepatocellular carcinoma cellsLiver progenitor cellsLiver-specific deletionCell-autonomous effectsHepatocellular carcinoma metastasisLoss of functionTumor cell linesHepatocellular carcinoma cellsLymph nodesHCC modelModel systemPoor prognosisPortal veinTumor suppressor
1999
Transforming growth factor β targeted inactivation of cyclin E:cyclin-dependent kinase 2 (Cdk2) complexes by inhibition of Cdk2 activating kinase activity
Nagahara H, Ezhevsky S, Vocero-Akbani A, Kaldis P, Solomon M, Dowdy S. Transforming growth factor β targeted inactivation of cyclin E:cyclin-dependent kinase 2 (Cdk2) complexes by inhibition of Cdk2 activating kinase activity. Proceedings Of The National Academy Of Sciences Of The United States Of America 1999, 96: 14961-14966. PMID: 10611320, PMCID: PMC24755, DOI: 10.1073/pnas.96.26.14961.Peer-Reviewed Original ResearchMeSH KeywordsCDC2-CDC28 KinasesCyclin ECyclin HCyclin-Dependent Kinase 2Cyclin-Dependent Kinase-Activating KinaseCyclin-Dependent KinasesCyclinsDown-RegulationEnzyme ActivationG1 PhaseHumansModels, BiologicalPhosphorylationProtein Serine-Threonine KinasesThreonineTransforming Growth Factor betaTumor Cells, CulturedConceptsTGF-beta treatmentInhibition of CDK2Cyclin ECyclin DGrowth factor betaGrowth factor βHepG2 hepatocellular carcinoma cellsHepatocellular carcinoma cellsTGF-beta signalingHuman HepG2 hepatocellular carcinoma cellsFactor betaCarcinoma cellsCyclin-dependent kinase 2 complexFactor βKinase activityCDK7 activityCDK4/6 activityHepG2 cellsWhole cell lysatesTumor suppressor proteinCDK2TreatmentCdk2 complexesArrestCells
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply